Podcasts about dmd

This episode of GEN's Touching Base spotlights the unexpected relationship between breathing low oxygen and restoration of neuron function in a mouse model of Parkinson's disease. In addition, a single gene therapy injected at birth now offers lasting protection from HIV in infant rhesus macaques. Rounding out our episode, we discuss key factors shaping this year's A-List of Top 10 U.S. Biopharma Clusters and recap the regulatory conflict surrounding Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy, Elevidys®—including the departure of Vinay Prasad, MD, the FDA official behind the agency's brief get-tough approach.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base:GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in MiceGEN, August 6, 2025Out of Thin Air: Hypoxia Reverses Parkinson's Symptoms in MiceBy Fay Lin, PhD GEN, August 6, 2025Early Gene Therapy Provides Lasting HIV Protection in Newborn PrimatesGEN, July 30, 2025StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT StocksBy Alex Philippidis, GEN Edge, August 3, 2025Sarepta to Resume Shipping DMD Gene Therapy to Ambulant PatientsBy Alex Philippidis, GEN Edge, July 28, 2025Sarepta Under Scrutiny, AstraZeneca's Big Bet, and AI vs. IDRsBy Alex Philippidis, Uduak Thomas, Fay Lin, PhD, Corinna Singleman, PhD, GEN, July 25, 2025About Face: Sarepta to Pause Elevidys Shipments TemporarilyBy Alex Philippidis, GEN Edge, July 21, 2025Touching Base PodcastHosted by Corinna Singleman, PhDBehind the BreakthroughsHosted by Jonathan D. Grinstein, PhDThe State of Biotech Summit Registration Hosted on Acast. See acast.com/privacy for more information.

The DMD is here! And we wanna talk about all the things! Let's get it going!

The DMD is here! And we chat about what to pack to go to Austin. And we chat about Sturgis.

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy Elevidys and growing scrutiny over the company’s transparency following multiple patient deaths. In this week’s episode of "The Top Line," we explore Sarepta’s brief standoff with the FDA over Elevidys, a short-lived marketing pause, and the regulator’s surprise reversal on the treatment. Fierce Pharma’s Fraiser Kansteiner and Angus Liu sit down with Fierce Biotech’s Gabrielle Masson to recap the story and discuss the broader implications the Elevidys saga may have for gene therapy, the FDA and the pharmaceutical industry. To learn more about the topics in this episode: Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Sarepta, bowing to FDA pressure, pauses shipments of Duchenne gene therapy Elevidys FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe See omnystudio.com/listener for privacy information.

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

The DMD is here! And we are playing music from all over the place for donations of $169!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.

In the latest podcast, Dr. Schmidt talks with Ralph Cooley, DDS, FAGD, and Arlene O'Brien, DMD, FAGD, who are members of ADA Legislative and Government Affairs Council and AGD representatives to the ADA Code Maintenance Committee. The Code Maintenance Committee is responsible for reviewing and updating dental coding systems. In their roles, they advocate for changes that benefit general dentists. New codes for 2026 include updates to anesthesia codes, a new cracked tooth testing code, and modifications to denture duplication and occlusal guard cleaning codes. They emphasize the importance of public input and collaboration between organizations. Listen now.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk has announced Maziar Mike Doustdar as its new CEO, along with a 5% reduction in its 2025 sales guidance. This decision comes as a response to the slowed growth of its semaglutide franchise in the U.S. Senate Democrats are currently looking into HHS Secretary RFK Jr.'s controversial move to dismiss all 17 members of the CDC's vaccine advisory committee. Astrazeneca CEO Pascal Soriot emphasized the importance of global collaboration in pharmaceutical research and development. Merck has allocated $3 billion to support upcoming product launches. In a surprising turn of events, the FDA has reversed its decision on Sarepta, now permitting DMD gene therapy for ambulatory patients.

Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of GEN's Touching Base, we discuss the company's response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&D, a heartwarming story about preventing mitochondrial disease involving eight babies from the U.K., and from the lab of Nobel Prize winner David Baker, PhD, AI that designs drugs for previously “undruggable” proteins.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.Listed below are links to the GEN stories referenced in this episode of Touching Base:About Face: Sarepta to Pause Elevidys Shipments TemporarilyBy Alex Philippidis, GEN Edge, July 21, 2025StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient DiesBy Alex Philippidis, GEN Edge, July 20, 2025Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient DeathsBy Alex Philippidis, GEN Edge, July 16, 2025AstraZeneca Commits $50B More to U.S. Manufacturing, R&D ProjectsBy Alex Philippidis, GEN Edge, July 22, 2025AstraZeneca's New $300M Plant Provides Control of Cell Therapy ProductionBy Gareth John Macdonald, GEN, May 14, 2025 Beyond Baby KJ: Next Steps in Manufacturing Genome Editing CuresGEN Live, July 30, 2025Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear TransferBy Julianna LeMieux, PhD GEN, July 16, 2025Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy TargetsBy Fay Lin, PhD GEN, July 18, 2025 Hosted on Acast. See acast.com/privacy for more information.

The DMD is here! And we chat about the staff's favorite OZZY and Black Sabbath songs!

Last week's public disclosure that a gene therapy from Sarepta had caused a third death led FDA to ask the company to stop distributing its DMD gene therapy Elevidys, a move the biotech has resisted. The deaths, and disputes between FDA and Sarepta, raise questions about the future of AAV gene therapies, as well as the future of FDA's platform technology designation. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the events surrounding Sarepta's gene therapies and discuss how FDA, industry and patient groups should come together to learn the lessons from the tragic, avoidable deaths.BioCentury's analysts also assess Monday's appointment of Stanford professor and biotech executive George Tidmarsh to lead FDA's Center for Drug Evaluation and Research, and check in on the latest trends in venture financings. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656537#biotech #biopharma #pharma #lifescience #GeneTherapy #AAVTherapy #Sarepta #Elevidys00:01 - Sponsor Message: IQVIA Biotech02:03 - Gene Therapy17:59 - Leading CDER27:00 - Venture ReportTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

On this week's episode, Eric Schmidt, Brad Loncar, Tim Opler and Tess Cameron kick off with a discussion on the surgein biotech M&A, with 2025 almost matching 2024's deal count and surpassing it in value ($40B YTD vs $30B), highlighting recent deals like Merck's acquisition of Verona and AbbVie's purchase of Capstan. The group debateswhether this signals a true “M&A wave,” noting pharma's $150 billion of LOE approaching and reduced macro uncertainty could be driving deal flow. They alsonote a current competitive dynamic around commercial-stage assets. Shifting to policy, Trump's “Big Beautiful Bill” introduces key IRA exemptions for rare diseases and on tariffs, the co-hosts note the market's quiet reaction andwonder if investors are becoming desensitized to D.C. headlines. As M&A steadies and drug launches hold strong despite pricing pressure, some stability seems to be on the way. On the regulatory front, the group praises the FDA'simproved communication under new leadership, citing their strong online presence and experience with media. Despite the FDA's recent rejection of Capricor's cell therapy for DMD, optimism remains about the therapy's potential. Despite the improved communication discussed earlier, questionsabout the FDA's transparency arise following the agency's issuance of CRLs to be more transparent; it remains uncertain if this trend will continue. Conversation shifts to data, overviewing KalVista's approval of Ekterly, thefirst oral calcineurin inhibitor approved for hereditary angioedema attacks and ProKidney's cell therapy that showed improved eGFR slope in CKD patients in aPhase 2 trial, skyrocketing shares. The episode closes with a conversation on obesity trends. *This episode aired on July 11, 2025. 

The DMD is here! Sounders tied. Mariners didn't play, and we talk calling people the wrong name!

The DMD is here! We love informing you! Plus let's chat about going to the zoo!

Up to 3,500 FDA staffers received their final walking papers Monday after the U.S. Supreme Court found last week that the government is “likely to succeed” in arguing that its overhaul of HHS is “lawful.” Meanwhile, FDA Commissioner Marty Makary floated policy changes for the agency, including a proposal to lower prescription drug user fees for the next iteration of the program, and one to offer speedier reviews to companies willing to lower the cost of their drugs.  Last week, the regulator opened its cache of complete response letters (CRLs), offering transparency into the rationale behind more than 200 recent rejections for ultimately approved therapies, including those for Eli Lilly's Alzheimer's drug Kisunla and Sarepta's Duchenne muscular dystrophy (DMD) treatment Vyondys 53. The FDA did not, however, release the CRLs for two new rejections: those of therapies from Ultragenyx and Capricor Therapeutics in Sanfilippo syndrome type A and cardiomyopathy associated with DMD, respectively. It was an especially rough week for Ultragenyx, which also, along with partner Mereo BioPharma, released seemingly negative Phase II/III data for their osteogenesis imperfecta therapy.  On a more positive note, two bustling therapeutic spaces continue to see positive data. In obesity, Hengrui Pharma's Kailera Therapeutics–partnered dual GLP-1/GIP receptor agonist elicited 17.7% average weight loss in a pivotal Chinese trial. And the psychedelic therapeutics space is again generating excitement with two recent positive readouts in treatment-resistant depression. BioSpace took a deep dive into the market reaction to these readouts for Compass Pathways and Beckley Psytech and atai Life Sciences, and what exactly investors are looking for in a successful psychedelic therapy.  Finally, we examine the progress of AI biotech unicorns and kick off our series on women in biopharma with profiles on Mayo Venture Partner Audrey Greenberg and the all-female CEO/R&D tandem at Acadia Pharmaceuticals.  

THE DMD is here! And we are ready to go! Cal Raleigh won the HOMERUN DERBY!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Takeda has taken the lead in the race for a narcolepsy treatment with back-to-back phase III wins for their drug Oveporexton. Investors are eagerly awaiting breakthroughs in using psychedelics to treat depression. Ultragenyx faced a setback as the FDA rejected their gene therapy for Sanfilippo syndrome, citing manufacturing issues. The FDA is considering speeding up reviews for companies that promise to lower drug costs. Market reaction to recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression shows the challenges psychedelic therapies must overcome for commercial viability. Rainin Micropro offers a solution to streamline NGS preparation with their 96-channel pipettor. The industry is also focused on precision diagnostics to support precision therapeutics in the future. AstraZeneca's Baxdrostat showed promising results in lowering blood pressure in a phase III trial. The ADA revealed R&D priorities for potential blockbuster obesity treatments. Relmada has abandoned development of a depression drug after three failed attempts.The challenges faced by psychedelic therapies in the treatment of depression are discussed, as recent readouts from Compass Pathways and Beckley Psytech/Atai in treatment-resistant depression have left investors wanting more. The market reaction highlights the hurdles psychedelic therapies must overcome to prove their commercial viability. Additionally, the importance of precision diagnostics in the development of next-generation precision oncology therapies is emphasized, stating that only with the adoption of digital imaging and AI-powered analysis will these therapies reach their full potential. The FDA has several important decisions lined up, including applications in lymphoma, rare diseases, and hormone deficiency, while the American Diabetes Association's annual meeting reveals R&D priorities for weight loss medicines. Topics discussed include Capricor's FDA rejection of a DMD cell therapy, the ALS community petitioning the FDA to reconsider Brainstorm's Nurown, and updates on COVID-19 vaccines and Alzheimer's drugs. Upcoming webinars and job opportunities in the biopharma industry are also included.

The DMD is here! And we wanna chat with you about CAMPING!

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA has rejected Capricor's therapy for Duchenne Muscular Dystrophy (DMD), causing shares to plunge due to insufficient evidence of effectiveness for cardiomyopathy associated with DMD. Lilly and Sarepta also received Complete Response Letters (CRLs) for their therapies. Moderna has won full approval for its COVID-19 vaccine for higher-risk kids, while Pacira has cut staff in San Diego. The FDA has released a cache of CRLs, providing insights into the journeys to market for various drugs. AbbVie has acquired Ichnos Glenmark's lead myeloma antibody, and Ultragenyx's stock plummeted after a late-stage trial disappointment. Kennedy postponed a preventive care panel meeting after a Supreme Court win. Transitioning from one piece of news to the next, let's move on to the webinar exploring digitization strategies for drug development. Stay tuned for more updates in the pharmaceutical industry.

Happy Thursday! The DMD is here and we are talking swear words! Plus donate now to Kicks for Kids at KISW.com!

THE DMD is here! Are you ready! Let's also chat about what you stole?

The DMD is here on a Tuesday! Plus we chat about rockstar names!

Happy Wednesday! The DMD is here! Let's chat about The Mariners losing.

The DMD is here! And let's chat about what your kid did for you!

The DMD is here! And we chat about role play!

In this episode of Talking Sleep, Drs. Michelle Cantwell and Aaron Glick discuss the updated American Academy of Dental Sleep Medicine (AADSM) Standards for Practice. Dr. Michelle Cantwell received her DMD through the University of Pittsburgh's School of Dental Medicine, where she also completed a three-year residency in prosthodontics. Following dental school, she served as a lieutenant commander in the US Navy. She is a diplomate of the ABDSM and the president-elect of the AADSM. She works in the pulmonary and sleep medicine department of WellSpan Health. Aaron Glick, DDS, FAGD, FICOI, D.ABDSM, is a dentist who has committed his practice to dental sleep medicine. He has been recognized as a “Top 10 Dentist to Watch” and works clinically utilizing teledentistry for efficient patient care. Dr. Glick educates fellow practitioners as the Mastery Program Director at the American Academy of Dental Sleep Medicine, focusing on mandibular advancement devices. Additionally, he is on the faculty at the University of Texas Health Science Center at Houston School of Dentistry. He actively lectures nationally and publishes on obstructive sleep apnea and technology. He enjoys all technologies and has a medical device and software programming background

DMD is here and we are ready to go!

The DMD is here! And we are ready to go on a hump day! Plus let's chat nick names!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sarepta Therapeutics faced a drop in shares due to a second death from acute liver failure in a patient receiving their DMD gene therapy. On the other hand, Sage Therapeutics had a positive outcome with a $795 million acquisition by Supernus, surpassing a bid from Biogen. Meanwhile, Lilly saw promising results in a phase I study of their amylin/tirzepatide combo for weight loss. J&J's dual-targeting CAR T-cell therapy showed an 80% complete response rate in early lymphoma studies, demonstrating potential in the field. In addition, Intellia Therapeutics is dedicated to developing potentially curative genome editing treatments for severe diseases, showing promise for future advancements in healthcare.

The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should drive all stakeholders to come together to figure out how to safely treat patients with this new modality. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the opportunity FDA, companies and patient advocates have to share data and identify a safe path forward for the gene therapy field, both in DMD and beyond.The analysts also review promising early data for amylin agonists to treat obesity from Metsera and Eli Lilly, and discuss the vision for FDA's future laid out by Commissioner Marty Makary and CBER director Vinay Prasad. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/656214#biotech #biopharma #pharma #lifescience #obesity #FDA #DMD00:01 - Sponsor Message: ICON Biotech01:19 - Gene Therapy Safety11:55 - Amylin in Obesity18:17 - FDA's FutureTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ep 324: Exploring Airway Health in Dentistry: Insights from Meggie Graham, DDS & Liz Turner, DMDThis week on the Untethered Podcast, Hallie welcomes Liz and Meggie from the Untethered Airway Health Center. They discuss the origins of their center and the importance of airway health in dentistry. Both Liz and Meggie dive into their personal journeys into airway-focused care and the establishment of their collaborative center. The conversation covers the holistic and interdisciplinary approach to treating tongue ties, the significance of pre and post-operative care, and how facial restrictions impact overall health. If this episode has resonated with you in some way, take a screenshot of you listening, post it to your Instagram Stories, and tag Hallie @halliebulkin and Meggie and Liz @untetheredairwayIn this episode, you'll hear:✔️ The origin of the Untethered Airway Health Center and its mission.✔️ Meggie's journey and collaboration with Liz.✔️ The importance of airway health in dentistry.✔️ Challenges in pediatric feeding and the role of myofunctional therapy.✔️ The value of comprehensive, interdisciplinary care.✔️ Cadaveric dissection and fascial connections.✔️ Identifying and treating airway issues in dentistry.✔️ The impact of orthodontics on airway health.✔️ Advocacy for children's health and educating providers and parents.✔️ New resources to advance airway health education.THIS WEEK:Doors to the Pediatric Feeding Hub are NOW OPEN! Get monthly mentorship from 5 experienced SLP and OT pediatric feeding specialists (plus the other members!) for a fraction of what a single consult would cost. https://pediatricfeedinghub.com/ LINKSGet to know Meggie Graham, DDS & Liz Turner, DMD on Instagram. Check out their website: https://untetheredairwayhealthcenter.com/aboutReady to turn your "myo eyes" on? Join our free training and learn how to screen patients for myo: https://www.feedthepeds.com/myo-webinarFind a myofunctional therapist here: www.themyodirectory.comConnect with Hallie on Instagram, Facebook & LinkedINHaven't left a review yet? Click here and thank you, as always, for being a listener! Want to watch more of the episode? Click here Hosted on Acast. See acast.com/privacy for more information.

Thursday is here! We got the DMD for you! And we chat about things you will always remember.

It's the DMD! And we are back from the Miles Montgomery Golf Tournament! Are we hungover? Probably. Also let's talk snakes!

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Anjali Rajpal, DMD, for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner! Dr. Rajpal practices cosmetic dentistry at Beverly Hills Dental Arts. During our 25-minute conversation, we discussed Dr. Rajpal's passion for hands-on creative work, like improving her patients' smiles. She explained that new electric tools vs air-powered ones have made the patient experience more comfortable. I Dr. Rajpal employs AI in her practice, which has many applications. Digital imaging powered by AI has replaced the old-fashioned and not entirely pleasant putty used to take impressions. Aesthetics can be fully realized with improved accuracy and efficiency. AI offers a "second set of eyes" to examine dental X-rays to ensure nothing is missed. Robots also assist with implant surgery. AI can also provide a look into the future for patients to see what their smile will look like after a complete makeover. To contact Dr. Rajpal, please check out her website:https://bhdentalarts.com Instagram, TikTok, YouTube: @beverlyhillsdentalartsPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

Friday is here! And we are ready with the DMD! Plus we chat all about friends!

The DMD is here! Let's go! Plus we chat about freak outs!

The DMD is here! And it's CHEESE DAY! What kind of cheese are you into?

The DMD is here! And we are ready to go! It's National Egg Day!

The DMD is here! And we dive into what crazy things you have seen at a show!

The DMD is here! And we chat about crazy pets! We know you have one!

We are here after Memorial day! Hope you are too and hope it was relaxing! Let's get going with the DMD!

Send us a textFlashing back to episode #72 of Fabulous Film & Friends way back in 2023, we covered Mission: Impossible – Dead Reckoning Part 1 and so we here on FFF felt duty bound to our fans to give our take on its follow up and what could very possibly be the final sequel to the entire M:I franchise, 2025's Mission: Impossible – The Final Reckoning directed by Christopher McQuarrie and starring Tom Cruise, Hayley Atwell, Simon Pegg, Ving Rhames, Pom Klementieff, Esai Morales, Shea Whigham, Greg Tarzan Davis, Henry Czerny and Angela Bassett. Keeping continuity, my guests this week are returnees from the 2023 podcast, my blockbuster crew David Johnson, DMD and Burton Brown. Does anyone remember what happened in Mission Impossible Dead Reckoning Part 1? Here's a callback to my synopsis from that podcast:Ethan Hunt and his team of Mission Impossiblers have to go rogue yet again to stop the world from  yada yada yada. Same old crap megalomaniac with a weapon this time it's AI. Or something.  Esai Morales is involved. I fell asleep twice so I didn't quite catch the relationship between the AI and Morales' Gabriel character.This movie seemed like more of the same old same old. But as a Tom Cruise running movie, it's a masterpiece, reaching an operatic Death in Venice level of running sophistication. So how does 2025's big follow up differ?This time Ethan Hunt and his rag tag team of crack superspies have to stop the AI Entity from blowing up the world as well as Gabriel from trying to harness its unbelievable power. Yet, instead of  running extravaganza, we are treated to the biggest boldest, hands down, accept no substitutes granddaddy of all info dump and flashback movies. Is it the best, the worst or somewhere in the middle of the series?Find out! Watch the video podcast on Youtube:https://youtu.be/dZfi-Cr8v20                                                                                                                                                       

The DMD is here! And Taryn tried to change a light at 345am!

The DMD is here! And we chat about what scared you as a kid!

Let's get it going! The DMD is here! And what was your crazy first day on the job?

The DMD is here! And Danny went to see SIX the musical at Paramount! What did you get into because of your kids?

The DMD is here! We wanna know if you have witnessed any meltdowns!

My guest is Dr. Staci Whitman, DMD, a board-certified functional dentist for kids and adults. We discuss the critical importance of oral care and the oral microbiome for brain and bodily health. We examine the negative effects of common oral care product ingredients such as alcohol, astringents, and bleaches. We also explore the history and real impact of fluoridated drinking water on oral, bone, and systemic health. Then we discuss healthy, lesser-known solutions for bad breath, canker sores, cavities, and teeth whitening. We cover how teeth can be made to repair their own cavities and the connection between oral health and cardiovascular health, male and female fertility, dementia, and cancer. This episode goes far beyond the best approaches to brushing and flossing and will be a valuable resource for anyone seeking to improve their oral health and appearance at any age. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://eightsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Joovv: https://joovv.com/huberman Function: https://functionhealth.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps 00:00:00 Dr. Staci Whitman 00:02:04 Oral Health & Oral Microbiome 00:05:01 Oral Healthcare Ingredients, Sodium Lauryl Sulfate (SLS); Canker Sores 00:08:45 Sponsors: Eight Sleep & BetterHelp 00:11:38 Cavities & Teeth De-/Remineralization, Fluoride 00:19:14 Cavities, Tool: Meal Frequency, Fasting 00:21:51 Sugar, “Dissolvable” Carbs & Cavities, Tools: Feed the Rainbow, Clean Diet 00:27:41 White Teeth, Bleaching, Hydroxyapatite, Mouth Breathing 00:34:34 Antibiotics, Gut & Oral Microbiome, Tool: Probiotics 00:36:20 Mouthwash, Alcohol, Astringents, Cardiovascular Risk, Bad Breath 00:39:54 Sponsors: AG1 & Joovv 00:42:21 Saliva, Dry Mouth, Salivary Analysis, Tools: Hydration; Nasal Breathing 00:47:23 Mouth vs. Nasal Breathing, Hard & Soft Tissue Issues 00:54:19 Deviated Septum, Therapies, Kids & Adults, Mouth Breathing & Sleep Disorders 01:00:42 Gum Health, Flossing; Sexual Health 01:01:50 Shifting to Nasal Breathing, Mouth Taping, Tools: 3-Minute Test, Kiss The Sky 01:05:53 Chewing Gum, Mastic Gum, Tool: Xylitol; Chewing Food, Breastfeeding 01:11:28 Sponsor: Function 01:13:15 Gum Disease, “Leaky Gums”, Cardiovascular Disease, Dementia, Cancer 01:20:05 Antibiotics, Ozone Therapy, Oil Pulling, Mold, Tool: Coconut Oil; Facial Trauma 01:28:07 Nicotine Gum & Pouches, Oral Health; Coffee, Teeth Whitening 01:34:16 Whole Foods, Hydroxyapatite Toothpaste; Tool: Testing Oral Microbiome 01:39:39 Water Fluoridation, History, Other Fluoride Sources, Neurocognitive Issues 01:54:57 Drinking Water & Fluoride, Toothpaste, Cavities 01:59:51 Sponsor: LMNT 02:01:07 Water Fluoridation & Levels 02:04:52 Oral Health & Fertility 02:07:03 Toothbrushing, Flossing, Waterpik, Tool: Toothbrushing & Meals 02:13:23 Teeth Spots & Markings, Fluorosis, Hypoplastic Enamel 02:19:10 Oral Health, Women, Pregnancy, Menopause & Burning Mouth 02:23:16 Geographic Tongue; Lip Balm; Mouth Breathing, Symmetrical Chewing 02:27:09 Tongue Tie, Chewing & Speech Function, Intervention 02:32:27 Red Light Therapy, Peptides & Exosomes 02:34:40 Mercury Fillings, Ceramic Composites, Retainers, Sealants 02:39:08 Dentists, Depression, Anxiety, Suicide; Insurance 02:45:05 Recap, Top Behavioral Tools for Oral Health, Tongue Scrapping 02:52:10 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures